Evaluation of Proclarix in the diagnostic work-up of prostate cancer.
Basil KaufmannSharon FischerAlcibiade AthanasiouNoémie LautenbachAnja WittigUwe BieriFlorian Alexander SchmidFranz von StauffenbergThomas Paul SchererDaniel EberliMichael A GorinRalph SchiessCédric PoyetPublished in: BJUI compass (2023)
Proclarix demonstrates high sensitivity in detecting csPCa but may still result in unnecessary biopsies. However, Proclarix density was able to outperform PSAD and Proclarix and was found to be useful in men with PI-RADS 3 findings by safely avoiding unnecessary biopsies without missing csPCa.